SCHEMBL17329201

SCHEMBL17329201

Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)NC3CCOC3=O)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.56
KMT2A Q03164 6/20 0.56
HSD17B10 Q99714 1/20 0.56
GAA P10253 2/20 0.52
LMNA P02545 2/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
TP53 P04637 1/20 0.49
MAPK1 P28482 1/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
KDM4E B2RXH2 2/20 0.48
MAPT P10636 2/20 0.48
POLB P06746 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
MMP9 P14780 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17329200 1.00 MEN1 (0.56) MEN1KMT2AHSD17B10GAALMNA
SCHEMBL17329235 0.89 MEN1 (0.54) MEN1KMT2AHSD17B10LMNAALDH1A1
SCHEMBL17329236 0.89 MEN1 (0.54) MEN1KMT2AHSD17B10LMNAALDH1A1
SCHEMBL17329223 0.89 MEN1 (0.47) MEN1KMT2AHSD17B10LMNAALDH1A1
SCHEMBL17329259 0.89 MEN1 (0.56) MEN1KMT2ALMNANPC1RAB9A
SCHEMBL17329230 0.89 MEN1 (0.52) MEN1KMT2AHSD17B10LMNATP53
SCHEMBL17329258 0.89 MEN1 (0.56) MEN1KMT2ALMNANPC1RAB9A
SCHEMBL17329231 0.89 MEN1 (0.52) MEN1KMT2AHSD17B10LMNATP53
SCHEMBL17329224 0.89 MEN1 (0.47) MEN1KMT2AHSD17B10LMNAALDH1A1
SCHEMBL17329183 0.89 PRMT1 (0.52) MEN1KMT2ALMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368217-A1 Derivative of Homoserine Lactone, and Preparation Method and Use Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2015-12-24 US claimed
EP-2955174-A1 DERIVATIVE OF HOMOSERINE LACTONE, AND PREPARATION METHOD AND USE THEREOF Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) 2015-12-16 EP claimed
US-9630939-B2 Derivative of homoserine lactone, and preparation method and use thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2017-04-25 US disclosed
US-20150368217-A1 Derivative of Homoserine Lactone, and Preparation Method and Use Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2015-12-24 US disclosed
EP-2955174-A1 DERIVATIVE OF HOMOSERINE LACTONE, AND PREPARATION METHOD AND USE THEREOF Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) 2015-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368217-A1 Derivative of Homoserine Lactone, and Preparation Method and Use Thereof LSS, HES1, SOS1 MEN1 589/4885KMT2A 3880/4885HSD17B10 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.